维普中文期刊产品整合服务
41篇 您的检索式:作者名="Fortea"
    题名 作者 年代 出处 被引量
1Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding显示文摘AIM To evaluate the long-term outcome of an acute hemodynamic response-guided protocol in which acute responders to intravenous propranolol received traditional nonselective beta-blockers(NSBBs) and acute nonresponders received carvedilol.METHODS Retrospective review of a protocol for primary prophylaxis of variceal bleeding guided by the acute hemodynamic response to intravenous propranolol. Fifty-two acute responders treated with traditional NSBB(i.e. propranolol or nadolol) were compared with 24 acute nonresponders receiving carvedilol. A second hemodynamic study was performed in 27 and 13 patients, respectively. The primary endpoint was development of first or further decompensation. Secondary endpoints included death from any cause, association between acute and chronic hemodynamic response, and baseline clinical and laboratory variables related to the acute hemodynamic response.RESULTS Acute responders and acute nonresponders presented similar 1, 2, and 3-year probabilities of first decompensation(NSBB: 0%, 13.7%, 26.1% vs carvedilol: 0%, 20%, 20%, P = 0.968) or further decompensation(21.2%, 26.1%, 40.9% vs 21.2%, 50.0%, 50.0%, P = 0.525). A previous episode of hepatic encephalopathy was the only independent predictor of decompensation [hazard ratio(95% confidence interval): 8.03(2.76-23.37)]. Mortality rates were similar in acute responders and acute nonresponders with compensated(P = 0.428) or decompensated cirrhosis(P = 0.429). No clinical, laboratory, endoscopic or hemodynamic parameter predicted the acute hemodynamic response. In patients receiving traditional NSBB, the acute and chronic changes of hepatic venous pressure gradient were correlated(r = 0.59, P = 0.001). Up to 69.2% of acute nonresponders gained chronic response with carvedilol.CONCLUSION Early identification and treatment with carvedilol of acute nonresponders to intravenous propranolol improves the clinical outcome of this high-risk group of patients, probably due to its greater effects for reducing portal pressure.José Ignacio Fortea ángela Puente Patricia Ruiz Iranzu Ezcurra Javier Vaquero Antonio Cuadrado María Teresa Arias-Loste Joaquín Cabezas Susana Llerena Paula Iruzubieta Carlos Rodríguez-Lope Patricia Huelin Fernando Casafont Emilio Fábrega Javier Crespo 2018World Journal of Clinical Cases2018,6,13:6
2Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints显示文摘E. M. M. Quigley J. Tack W. D. Chey S. S. Rao J. Fortea M. Falques C. Diaz S. J. Shiff M. G. Currie J. M. Johnston 2012Aliment Pharmacol Ther2012,,1:3
3Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease显示文摘Fortea J Vilaplana E Alcolea D 2014Ann Neurol2014,76,2:1
4Kinetic characterisation and thermal inactivation study of polyphenoloxidase and peroxidase from table grape 显示文摘FORTEA M I LOPEZ-MIRANDA S SERRANO-MARTNEZ A 2009Food Chemistry2009,113,:1
5Early over expression of messenger RNA for multiple genes,including insulin,in the pancreatic lymph nodes of NOD mice is associated with islet autoimmunity显示文摘Regnault B Osorio Y Fortea J 2009BMC Med Genomics2009,2,4:1
6Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer′s disease vulnerable areas显示文摘Fortea J Sala-Llonch R Bartres-Faz D 2011Biol Psychiatry2011,70,2:1
7Hirschprung's disease in adults显示文摘Fortea Sanchis C Martinea Ramos D Rivadulla Serrano I 2011Rey Esp Enferm Dig2011,103,3:1
8Effect of time and cerebrovascular symptoms on the prevalence of microembdic signals in patients with cervical carotid stenosis显示文摘Fortea A M Babikian VL Hyde C 1996Stroke1996,27,:1
9Insight into the uncoupling mechanism of sarcoplasmic reticnlum ATPase using the phosphorylating substrate UTP显示文摘FORTEA M I SOLER F BELDA F F 2000Biological Chemistry2000,275,12:1
10Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints显示文摘E. M. M. Quigley J. Tack W. D. Chey S. S. Rao J. Fortea M. Falques C. Diaz S. J. Shiff M. G. Currie J. M. Johnston 2012Aliment Pharmacol Ther2012,,1:1
11Novel potential targets for prevention of arterial restenosis:insights from the pre–clinical research显示文摘ForteA RinaldiB BerrinoL 2014Clin Sci(Lond)2014,127,61:1
12Inguinal bernioplasty: the gold standard of hernia repair显示文摘ForteA D'UrsoA Palumbo P 2003Hernia2003,7,1:1
13Product formation in the Prato reaction on Sc3N@D5h-C80:Preference for-bonds,and not pyracylenic bonds显示文摘Osuna S Rodriguez Fortea A Poblet J M 2012Chemical Communications2012,48,:1
14Kinetic characterisation and thermal inactivation study of polyphenol oxidase and peroxidase from table grape (Crimson Seedless)显示文摘Fortea M I S Lopez-Miranda 2009Food Chemistry2009,113,:1
15Cerebrospinal fluidbeta - amyloid and phospho - tau biomarker interactions af-fecting brain structure in preclinical Alzheimer disease 显示文摘Fortea J Vilaplana E Alcolea D 2014Ann Neurol2014,,:1
16Laser cutting of high-vitrified ceramic materials:development of a method using a Nd∶YAG laser to avoid catastrophic breakdown显示文摘COSP J P RAMíREZ DEL VALLE A J FORTEA J G 2002Materials Letters2002,55,4:1
17Kinetic characterisation and thermal inactivation study of polyphenol oxidase and peroxidase from table grape显示文摘Fortea M I Lopez-Miranda S Serrano-Martnez A 2009Food Chemistry2009,113,:1
18Irritable bowel syndrome with constipation:a European-focused systematic literature review of disease burden显示文摘Fortea J Prior M 2013J Med Econ2013,16,:1
19Encapsulation of Quercetin and Myricetin in Cyclodextrins at Acidic pH显示文摘LUCAS -ABELLAN CARMEN FORTEA ISABEL ABALDON JOSE ANTONIO 2008Journal of Agricultural and Food Chemistry2008,56,1:1
20Follicular mucinosis secondary to captopril-induced photoallergy显示文摘P6rez-Ferriols A Martinez-Mench6n T Fortea JM 2005ActasDermosifiliogr2005,96,3:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费